Hackam Daniel G, Goodman Shaun G, Anand Sonia S
Division of Clinical Pharmacology and Toxicology, Sunnybrook & Women's College Health Sciences Centre, Toronto, Canada.
Am Heart J. 2005 Jul;150(1):35-40. doi: 10.1016/j.ahj.2005.01.008.
Peripheral artery disease (PAD) is a problem frequently encountered by physicians who care for patients with coronary heart disease, diabetes mellitus, renal insufficiency, congestive heart failure, or stroke. Patients with PAD are at heightened risk of myocardial infarction and stroke and are 6 times more likely to die of cardiovascular causes than persons without the disease. There is an urgent need for therapies that reduce the incidence of vascular complications among patients with PAD. In recent years, a number of risk-lowering therapies have been validated by randomized controlled trials enrolling large numbers of patients with PAD. The available evidence supports aggressive lifestyle modification as well as the provision of an antiplatelet agent, an HMGCoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitor, and an angiotensin-converting enzyme inhibitor for cardiovascular protection in patients with PAD. As a result of their high baseline risk and the proven effectiveness of these interventions, most patients with PAD will benefit substantially from aggressive medical therapy.
外周动脉疾病（PAD）是冠心病、糖尿病、肾功能不全、充血性心力衰竭或中风患者的护理医生经常遇到的问题。患有PAD的患者发生心肌梗死和中风的风险增加，死于心血管疾病的可能性是未患该疾病者的6倍。迫切需要降低PAD患者血管并发症发生率的治疗方法。近年来，一些降低风险的治疗方法已通过纳入大量PAD患者的随机对照试验得到验证。现有证据支持积极改变生活方式，以及为PAD患者提供抗血小板药物、HMGCoA（3-羟基-3-甲基戊二酰辅酶A）还原酶抑制剂和血管紧张素转换酶抑制剂以进行心血管保护。由于PAD患者基线风险高且这些干预措施已被证实有效，大多数PAD患者将从积极的药物治疗中大幅获益。
